Physician profile
Derek N Cunningham
NPI 1265407084
$940,293.57
in general payments reported to CMS, 2019-2025
31 companies · $198K in 2025
The $198K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140K · 2020: $69K · 2021: $125K · 2022: $140K · 2023: $146K · 2024: $122K · 2025: $198K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $227K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139K · Travel and Lodging: $49K · Consulting Fee: $36K · Food and Beverage: $15K · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $227,100.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $139,034.34 |
| Travel and Lodging | $48,745.82 |
| Consulting Fee | $35,625.00 |
| Food and Beverage | $15,206.88 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $244,033.83 | 2019-2025 | Cequa, Bromsite, Xelpros |
| Bausch & Lomb Americas INC. | $238,544.68 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $145,287.09 | 2019-2025 | Tearcare System |
| Shire North American Group INC | $56,229.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55,730.10 | 2019-2023 | |
| Alcon Vision LLC | $48,558.38 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Kala Pharmaceuticals, INC. | $42,993.52 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35,917.26 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $27,846.67 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $15,030.00 | 2019-2021 | |
| Oyster Point Pharma, INC. | $9,627.71 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $7,370.97 | 2024-2025 | Vevye |
| Alcon Research LLC | $2,700.00 | 2025 | Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $2,048.21 | 2019-2022 | |
| Bausch Health US, LLC | $2,000.00 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $1,750.00 | 2020 | |
| Beaver-Visitec International, INC. | $1,000.00 | 2019 | |
| Seagen INC. | $990.00 | 2022 | |
| Tearlab Corp | $715.34 | 2019-2023 | Tearlab Osmolarity System |
| Carl Zeiss Meditec, INC. | $411.17 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $311.70 | 2024-2025 | Xdemvy |
| Abbvie INC. | $248.39 | 2022-2025 | Durysta |
| Glaukos Corporation | $204.49 | 2024 | Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Ani Pharmaceuticals, INC. | $164.48 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Ocular Therapeutix, INC. | $136.64 | 2020-2023 | Dextenza |
| Rxsight INC | $120.41 | 2023-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Dompe US, INC. | $115.83 | 2019-2025 | Oxervate |
| Thea Pharma INC. | $103.29 | 2022-2025 | Iyuzeh |
| Biotissue Holdings INC. | $56.29 | 2019-2024 | |
| Carl Zeiss Meditec USA, INC. | $32.95 | 2024 | |
| Eyepoint US, INC. | $14.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.